Refine
Year of publication
Document Type
- Preprint (665)
- Article (374)
- Working Paper (1)
Has Fulltext
- yes (1040)
Is part of the Bibliography
- no (1040)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- Collective Flow (4)
- Handschrift (4)
- Jets (4)
- Quark-Gluon Plasma (4)
Institute
- Physik (1025)
- Frankfurt Institute for Advanced Studies (FIAS) (955)
- Informatik (921)
- Medizin (8)
- Informatik und Mathematik (3)
- Hochschulrechenzentrum (2)
- Center for Financial Studies (CFS) (1)
- House of Finance (HoF) (1)
- Sustainable Architecture for Finance in Europe (SAFE) (1)
- Wirtschaftswissenschaften (1)
Fast vor der Haustüre : zur Wiederentdeckung des verschollenen Predigtfragments Morvay/Grube T 128
(2021)
In einer kleinen, nur neunzeiligen Miszelle teilte J. A. Stargardt von der gleichnamigen Berliner Antiquariatsbuchhandlung 1869 mit, dass er bei einer Auktion aus dem Nachlass von August Vilmar ein Pergamentblatt in Quart aus dem 15. Jahrhundert mit deutschen Predigten erworben habe, das mit folgenden Worten beginnt: "Frocht gebrengen Mach der bose baum | Nyet gude frocht gebrengen." [...] Dank der zunehmenden digitalen Bereitstellung von Materialien und Hilfsmitteln ist es nun gelungen, die Spur zu diesem verschollenen Fragment wieder aufzunehmen und es schließlich zu orten.
Karin Schneiders detaillierte Beschreibung des Fragments lässt keinen Zweifel daran, dass das Münchner Rudolf-Fragment und das verschollene "Reimbibel"-Fragment aus dem Würzburger Schottenkloster ein und dasselbe sind. Während man also beim Fragment aus dem Würzburger Schottenkloster nicht wusste, wohin es gelangt war, wusste man beim Münchner Fragment nicht genau, woher es gekommen war. Nun steht aber unzweifelhaft fest: Das verschollene Würzburger Fragment und das 'neue' Münchner Fragment sind identisch.
Background: The approval of everolimus (EVE) for the treatment of angiomyolipoma (2013), subependymal giant cell astrocytoma (2013) and drug-refractory epilepsy (2017) in patients with tuberous sclerosis complex (TSC) represents the first disease-modifying treatment option available for this rare and complex genetic disorder. Objective: The objective of this study was to analyse the use, efficacy, tolerability and treatment retention of EVE in patients with TSC in Germany from the patient’s perspective. Methods: A structured cross-age survey was conducted at 26 specialised TSC centres in Germany and by the German TSC patient advocacy group between February and July 2019, enrolling children, adolescents and adult patients with TSC. Results: Of 365 participants, 36.7% (n = 134) reported the current or past intake of EVE, including 31.5% (n = 115) who were taking EVE at study entry. The mean EVE dosage was 6.1 ± 2.9 mg/m2 (median: 5.6 mg/m2, range 2.0–15.1 mg/m2) in children and adolescents and 4 ± 2.1 mg/m2 (median: 3.7 mg/m2, range 0.8–10.1 mg/m2) in adult patients. An early diagnosis of TSC, the presence of angiomyolipoma, drug-refractory epilepsy, neuropsychiatric manifestations, subependymal giant cell astrocytoma, cardiac rhabdomyoma and overall multi-organ involvement were associated with the use of EVE as a disease-modifying treatment. The reported efficacy was 64.0% for angiomyolipoma (75% in adult patients), 66.2% for drug-refractory epilepsy, and 54.4% for subependymal giant cell astrocytoma. The overall retention rate for EVE was 85.8%. The retention rates after 12 months of EVE therapy were higher among adults (93.7%) than among children and adolescents (88.7%; 90.5% vs 77.4% after 24 months; 87.3% vs 77.4% after 36 months). Tolerability was acceptable, with 70.9% of patients overall reporting adverse events, including stomatitis (47.0%), acne-like rash (7.7%), increased susceptibility to common infections and lymphoedema (each 6.0%), which were the most frequently reported symptoms. With a total score of 41.7 compared with 36.8 among patients not taking EVE, patients currently being treated with EVE showed an increased Liverpool Adverse Event Profile. Noticeable deviations in the sub-items ‘tiredness’, ‘skin problems’ and ‘mouth/gum problems’, which are likely related to EVE-typical adverse effects, were more frequently reported among patients taking EVE. Conclusions: From the patients’ perspective, EVE is an effective and relatively well-tolerated disease-modifying treatment option for children, adolescents and adults with TSC, associated with a high long-term retention rate that can be individually considered for each patient. Everolimus therapy should ideally be supervised by a centre experienced in the use of mechanistic target of rapamycin inhibitors, and adverse effects should be monitored on a regular basis.
Non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) are the leading causes of liver disease worldwide. To identify disease-specific pathomechanisms, we analyzed the lipidome, metabolome and immune cell recruitment in livers in both diseases. Mice harboring ASH or NASH had comparable disease severities regarding mortality rate, neurological behavior, expression of fibrosis marker and albumin levels. Lipid droplet size was higher in NASH than ASH and qualitative differences in the lipidome were mainly based on incorporation of diet-specific fatty acids into triglycerides, phosphatidylcholines and lysophosphatidylcholines. Metabolomic analysis showed downregulated nucleoside levels in both models. Here, the corresponding uremic metabolites were only upregulated in NASH suggesting stronger cellular senescence, which was supported by lower antioxidant levels in NASH as compared to ASH. While altered urea cycle metabolites suggest increased nitric oxide synthesis in both models, in ASH, this depended on increased L-homoarginine levels indicating a cardiovascular response mechanism. Interestingly, only in NASH were the levels of tryptophan and its anti-inflammatory metabolite kynurenine upregulated. Fittingly, high-content immunohistochemistry showed a decreased macrophage recruitment and an increased polarization towards M2-like macrophages in NASH. In conclusion, with comparable disease severity in both models, higher lipid storage, oxidative stress and tryptophan/kynurenine levels were seen in NASH, leading to distinct immune responses.